Literature DB >> 28025026

Hyperdynamic Right Heart Function in Graves' Hyperthyroidism Measured by Echocardiography Normalises on Restoration of Euthyroidism.

Stephanie L Teasdale1, Warrick J Inder2, Michael Stowasser3, Tony Stanton4.   

Abstract

BACKGROUND: Graves' hyperthyroidism commonly causes tachycardia and may result in pulmonary hypertension and high output cardiac failure. There is limited information regarding the effect of treatment on cardiac function measured using modern echocardiographic techniques.
METHODS: Eight individuals with Graves' hyperthyroidism, aged 22-64 years, underwent comprehensive transthoracic echocardiography at three time points: before treatment, two weeks after commencement of carbimazole, and at six months or more when euthyroid. Exercise capacity was assessed using the 6-minute-walk-distance (6MWT), and quality of life was assessed by Medical Outcome Study 36-item Short-Form Health Status Survey.
RESULTS: All individuals were rendered euthyroid by final assessment. At presentation, there was evidence of hyperdynamic right ventricular function as measured by peak systolic velocity of the free wall of the tricuspid annulus, tricuspid annular plane systolic excursion and right ventricular ejection fraction, which normalised after resolution of thyrotoxicosis. Baseline heart rate correlated significantly with severity of the thyrotoxicosis for either free T4 (r = 0.91, p=0.01) or free T3 (r=0.94, p=0.001). No individual had measurable pulmonary hypertension. Cardiac output was significantly lower in the euthyroid compared to the thyrotoxic state (p=0.03). A higher baseline TSH-receptor antibody titre corresponded to a greater improvement in exercise capacity (r=0.76, p<0.05) and physical quality of life (r=0.73, p<0.05) on resolution of the hyperthyroidism.
CONCLUSION: Graves' hyperthyroidism causes increased cardiac output and a hyperdynamic right ventricle which normalise on restoration of the euthyroid state.
Copyright © 2016 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Graves; Pulmonary hypertension; Right heart function; Strain; TAPSE; Thyroid

Mesh:

Year:  2016        PMID: 28025026     DOI: 10.1016/j.hlc.2016.10.007

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  6 in total

1.  Right ventricular dysfunction and pulmonary hypertension: a neglected presentation of thyrotoxicosis.

Authors:  Carolina Shalini Singarayar; Foo Siew Hui; Nicholas Cheong; Goay Swee En
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2018-05-16

2.  Echocardiographic evolution of pulmonary hypertension in female patients with hyperthyroidism.

Authors:  Cristina Tudoran; Mariana Tudoran; Mihaela Vlad; Melania Balas; Gheorghe Nicusor Pop; Florina Parv
Journal:  Anatol J Cardiol       Date:  2018-09       Impact factor: 1.596

3.  Pulmonary Hypertension and Hypocholesterolemia Secondary to Thyrotoxicosis.

Authors:  Narangoda Liyanage Ajantha Shyamali; Chandrike Ponnamperuma
Journal:  Case Rep Endocrinol       Date:  2020-11-12

4.  Evaluation of diastolic function in newly diagnosed hyperthyroid patients with preserved left ventricular systolic function.

Authors:  Maryam Shojaeifard; Zahra Davoudi; Azam Erfanifar; Hamed Fattahi Neisiani; Sajad Erami; Hooman Bakhshandeh; Khadije Mohammadi
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-11-19

Review 5.  Cardiovascular Involvement in Thyrotoxicosis Resulting in Heart Failure: The Risk Factors and Hemodynamic Implications.

Authors:  Ciri C Raguthu; Harini Gajjela; Iljena Kela; Chandra L Kakarala; Mohammad Hassan; Rishab Belavadi; Sri Vallabh Reddy Gudigopuram; Ibrahim Sange
Journal:  Cureus       Date:  2022-01-13

6.  The Association of Autoantibodies in Hyperthyroid Heart Disease Combined with Pulmonary Hypertension.

Authors:  Xiujuan Zhang; Lin Chen; Jianping Sheng; Chaoying Li; Yong He; WenXia Han
Journal:  Int J Endocrinol       Date:  2019-12-01       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.